HBM Holdings Ltd. (HK:2142) has released an update.
HBM Holdings Limited has announced the re-submission of the biologics license application for their potential autoimmune disease treatment, batoclimab (HBM9161), to China’s drug regulatory authority. Batoclimab, an advanced FcRn inhibitor, could provide a breakthrough for a range of autoimmune diseases in Greater China, though the company warns that success is not guaranteed and urges caution among investors and shareholders.
For further insights into HK:2142 stock, check out TipRanks’ Stock Analysis page.
